Corvus Pharmaceuticals Receives Orphan Drug Designation for Soquelitinib in Treating T Cell Lymphoma
Friday, February 09, 2024
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) has announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for soquelitinib, a clinical-stage biopharmaceutical company's lead ITK inhibitor candidate, for the treatment of T cell lymphoma. This designation marks a significant step forward in the company's efforts to address the urgent medical needs of patients with this condition.
Corvus, emphasized the gravity of T cell lymphoma, noting its aggressive nature and poor prognosis. He highlighted the pressing need for novel therapies, considering the limited efficacy and significant toxicity associated with current treatment options. Notably, there are currently no FDA-approved agents for relapsed PTCL, underscoring the importance of advancing soquelitinib.
FDA Orphan Drug Designation is reserved for investigational treatments targeting rare medical diseases or conditions affecting fewer than 200,000 people in the United States. This designation offers various benefits to drug developers, including support throughout the drug development process, tax credits for clinical expenses, exemptions from certain FDA fees, and seven years of exclusive marketing rights following approval.
Corvus Pharmaceuticals anticipates the initiation of a Phase 3 registrational clinical trial for soquelitinib in patients with relapsed peripheral T cell lymphoma (PTCL) in the second quarter of 2024. This development represents a crucial advancement in the pursuit of effective treatments for this challenging medical condition.
Source: globenewswire.com
